It-hMSC is under clinical development by CardioCell and currently in Phase II for Congestive Heart Failure (Heart Failure). According to GlobalData, Phase II drugs for Congestive Heart Failure (Heart Failure) have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how It-hMSC’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
It-hMSC overview
Stem cell therapy (Stemedyne-MSC) is under development for the treatment of post-acute sequelae of COVID 2019 (PASC or Long COVID), ischemic stroke, chronic heart failure, traumatic brain injury and Alzheimer's disease. The therapy is administered through intravenous route. Mesenchymal stem cells (MSCs) are multipotent stem cells found in bone marrow. It was also under development for the treatment of acute lung injury, bacterial sepsis, acute myocardial infarction, diabetic retinopathy and ageing and dermatological disorders.
It was under development for the treatment of non-ischemic heart failure, and peripheral arterial disease.
CardioCell overview
CardioCell, a subsidiary of Stemedica Cell Technologies Inc, is a biotechnology company that explores therapeutic applications of ischemia-tolerant mesenchymal stem cells. The company has an exclusive worldwide license from Stemedica for the exploration of therapeutic indications for three major cardiovascular areas such as acute myocardial infarction, chronic heart failure and peripheral artery disease. It utilizes allogeneic stem cells derived from the bone marrow to develop off-the-shelf products for cardiovascular indication. CardioCell also offers services in the areas of arrhythmia, atherosclerosis, hypertension, congestive heart failure and endocarditis. CardioCell is headquartered in San Diego, California, the US.
For a complete picture of It-hMSC’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
